ACIU AC Immune Ltd

USD 3.44 0.00 0
Icon

AC Immune Ltd (ACIU) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.44

0.00 (0.00)%

USD 0.34B

0.11M

USD 16.00(+365.12%)

USD 10.00 (+190.70%)

Icon

ACIU

AC Immune Ltd (USD)
COMMON STOCK | NSD
USD 3.44
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.34B

USD 10.00 (+190.70%)

USD 3.44

AC Immune Ltd (ACIU) Stock Forecast

Show ratings and price targets of :
USD 16.00
(+365.12%)

Based on the AC Immune Ltd stock forecast from 1 analysts, the average analyst target price for AC Immune Ltd is USD 16.00 over the next 12 months. AC Immune Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AC Immune Ltd is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, AC Immune Ltd’s stock price was USD 3.44. AC Immune Ltd’s stock price has changed by +12.42% over the past week, -14.00% over the past month and +53.57% over the last year.

No recent analyst target price found for AC Immune Ltd
No recent average analyst rating found for AC Immune Ltd

Company Overview AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to...Read More

https://www.acimmune.com

Building B, Lausanne, Switzerland, 1015

126

December

USD

USA

Adjusted Closing Price for AC Immune Ltd (ACIU)

Loading...

Unadjusted Closing Price for AC Immune Ltd (ACIU)

Loading...

Share Trading Volume for AC Immune Ltd Shares

Loading...

Compare Performance of AC Immune Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACIU

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To AC Immune Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD90.49B 26.38 17.57

ETFs Containing ACIU

Symbol Name ACIU's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About AC Immune Ltd (ACIU) Stock

Based on ratings from 1 analysts AC Immune Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on ACIU's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ACIU is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.

ACIU stock's Price/Earning ratio is 11.63. Our analysis grades ACIU stock's Price / Earning ratio at F. This means that ACIU stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ACIU may be a overvalued for its sector.

The last closing price of ACIU's stock was USD 3.44.

The most recent market capitalization for ACIU is USD 0.34B.

Based on targets from 1 analysts, the average taret price for ACIU is projected at USD 16.00 over the next 12 months. This means that ACIU's stock price may go up by +365.12% over the next 12 months.

We can't find any ETFs which contains AC Immune Ltd's stock.

As per our most recent records AC Immune Ltd has 126 Employees.

AC Immune Ltd's registered address is Building B, Lausanne, Switzerland, 1015. You can get more information about it from AC Immune Ltd's website at https://www.acimmune.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...